Data / Form D filings / Angiocrine Bioscience, Inc.
Angiocrine Bioscience, Inc.: Form D filings
Angiocrine Bioscience, Inc., a biotechnology company in San Diego, CA, filed 3 Form D notices with the SEC between 2013 and 2025. The latest, on September 5, 2025, reports $2.1 million sold of a $3 million offering to 16 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 11585 SORRENTO VALLEY RD, STE 109, San Diego, CA, 92121
- Phone
- (858) 436-8047
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1569052
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025 | New notice | $3,000,000 | $2,100,000 | $900,000 | 16 | Aug 21, 2025 | sec.gov |
| Oct 15, 2021 | New notice | $99,372,730 | $58,121,796 | $41,250,934 | 78 | Oct 1, 2021 | sec.gov |
| Mar 13, 2013 | New notice | $4,999,998 | $3,999,999 | $999,999 | 1 | Mar 1, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| David L Parkinson | Director | |
| Jeffrey L Port | Director | |
| John T Lomoro | Executive Officer | |
| Paul W Finnegan | Executive Officer, Director | |
| John R Jaskowiak | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Sep 1, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Angiocrine Bioscience, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.